-+ 0.00%
-+ 0.00%
-+ 0.00%

Ruibo Biotech (06938) expects revenue of about 311 million to 436 million yuan in the first half of the year, an increase of about 200% to 320% year-on-year

Zhitongcaijing·07/29/2026 10:25:41
Listen to the news

Zhitong Finance App News, Ruibo Bio-B (06938) announced that the group expects to obtain revenue of about 311 million to 436 million yuan in the first half of 2026, an increase of about 200% to 320% over the same period in 2025, mainly due to partial confirmation of license revenue under the Group's exclusive global licensing cooperation with Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), as well as revenue confirmed when the Group cooperated with Boehringer Ingelheim International to reach milestones. The development and commercialization of small interfering RNA (siRNA) therapy for steatohepatitis associated with metabolic dysfunction (MASH) formed the main driving force for the Group's revenue growth during the reporting period.